A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)
A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)
ClinicalTrials.gov ID: NCT02314117
Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company (Responsible Party)
Last Update Posted: 2021-08-26
Brief Summary:
The main purpose of this study is to evaluate the efficacy of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.
Official Title:
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)
Intervention / Treatment:
- Drug: Ramucirumab
- Drug: Capecitabine
- Drug: Cisplatin
- Drug: Placebo
- Drug: Fluorouracil
| Category | Value |
|---|---|
| Study Start (Actual) | 2015-01-20 |
| Primary Completion (Estimated) | 2017-01-17 |
| Study Completion (Estimated) | 2020-08-14 |
| Enrollment (Estimated) | 645 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
15372
I4T-MC-JVCU (Other Identifier) (OTHER: Eli Lilly and Company) 2014-002240-40 (EudraCT Number) |